Published in J Clin Oncol on October 10, 2007
Elective clinical target volumes for conformal therapy in anorectal cancer: a radiation therapy oncology group consensus panel contouring atlas. Int J Radiat Oncol Biol Phys (2008) 2.45
RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal. Int J Radiat Oncol Biol Phys (2012) 2.12
Plan comparison of volumetric-modulated arc therapy (RapidArc) and conventional intensity-modulated radiation therapy (IMRT) in anal canal cancer. Radiat Oncol (2010) 1.25
Anal squamous cell carcinoma: an evolution in disease and management. World J Gastroenterol (2014) 1.03
Anal cancer - a review. Int J Health Sci (Qassim) (2012) 1.01
Anal cancer treatment: current status and future perspectives. World J Gastroenterol (2015) 0.97
Intensity-Modulated Radiation Therapy vs. 3D Conformal Radiation Therapy for Squamous Cell Carcinoma of the Anal Canal. Gastrointest Cancer Res (2013) 0.97
Radiotherapy with or without chemotherapy in the treatment of anal cancer: 20-year experience from a single institute. Strahlenther Onkol (2012) 0.97
IMRT for locally advanced anal cancer: clinical experience of the Montpellier Cancer Center. Radiat Oncol (2012) 0.93
Intensity-modulated radiation therapy for rectal carcinoma can reduce treatment breaks and emergency department visits. Int J Surg Oncol (2012) 0.92
Clinical implementation of volumetric intensity-modulated arc therapy (VMAT) with ERGO++. Strahlenther Onkol (2010) 0.88
Quality of life and tumor control after short split-course chemoradiation for anal canal carcinoma. Radiat Oncol (2010) 0.88
Efficacy and toxicity of chemoradiation in patients with anal cancer--a retrospective analysis. Radiat Oncol (2014) 0.86
Radiotherapy for patients with the human immunodeficiency virus: are special precautions necessary? Cancer (2010) 0.85
Does gap-free intensity modulated chemoradiation therapy provide a greater clinical benefit than 3D conformal chemoradiation in patients with anal cancer? Radiat Oncol (2012) 0.82
Cardiac avoidance in breast radiotherapy: many choices for a worthwhile objective. Front Oncol (2014) 0.81
Primary rectal squamous cell carcinoma treated with surgery and radiotherapy. World J Gastroenterol (2014) 0.81
Impact of bone marrow radiation dose on acute hematologic toxicity in cervical cancer: principal component analysis on high dimensional data. Int J Radiat Oncol Biol Phys (2010) 0.81
Volumetric modulated arc therapy (VMAT) in the combined modality treatment of anal cancer patients. Br J Radiol (2016) 0.80
Intensity-Modulated Radiotherapy (IMRT) vs Helical Tomotherapy (HT) in Concurrent Chemoradiotherapy (CRT) for Patients with Anal Canal Carcinoma (ACC): an analysis of dose distribution and toxicities. Radiat Oncol (2015) 0.80
Current understanding and potential immunotherapy for HIV-associated squamous cell carcinoma of the anus (SCCA). World J Surg (2009) 0.80
HIV- positive anal cancer: an update for the clinician. J Gastrointest Oncol (2010) 0.79
Technical aspects of radiation therapy for anal cancer. J Gastrointest Oncol (2014) 0.79
Anal cancer treated with radio-chemotherapy: correlation between length of treatment interruption and outcome. Int J Colorectal Dis (2009) 0.78
Clinical experience of SIB-IMRT in anal cancer and selective literature review. Radiat Oncol (2014) 0.78
Human papillomavirus-related diseases in HIV-infected individuals. Curr Opin Oncol (2008) 0.78
Modeling early haematologic adverse events in conformal and intensity-modulated pelvic radiotherapy in anal cancer. Radiother Oncol (2015) 0.77
The evolving scenario of non-AIDS-defining cancers: challenges and opportunities of care. Oncologist (2014) 0.77
Long-term outcomes of chemoradiation for anal cancer patients. Yonsei Med J (2013) 0.76
Epidermoid cancers of the anal canal: current treatment. Clin Colon Rectal Surg (2009) 0.76
Proposed genitalia contouring guidelines in anal cancer intensity-modulated radiotherapy. Br J Radiol (2015) 0.75
Dose planning objectives in anal canal cancer IMRT: the TROG ANROTAT experience. J Med Radiat Sci (2015) 0.75
Management of two cases of recurrent anal carcinoma. Case Rep Oncol (2013) 0.75
Correlation between bone marrow dose volumes and acute hematological toxicity in postoperative gynecological cancer patients. Pak J Med Sci (2017) 0.75
Background and Current Treatment of Squamous Cell Carcinoma of the Anus. Oncol Ther (2016) 0.75
Genital invasion or perigenital spread may pose a risk of marginal misses for Intensity Modulated Radiotherapy (IMRT) in anal cancer. Radiat Oncol (2016) 0.75
Chemo-radiation with or without mandatory split in anal carcinoma: experiences of two institutions and review of the literature. Radiat Oncol (2010) 0.75
Predictors of acute toxicities during definitive chemoradiation using intensity-modulated radiotherapy for anal squamous cell carcinoma. Acta Oncol (2015) 0.75
Potential and limitations of intensity-modulated radiotherapy in anal cancer. J Clin Oncol (2008) 0.75
Long-term outcomes and toxicities of a large cohort of anal cancer patients treated with dose-painted IMRT per RTOG 0529. Adv Radiat Oncol (2017) 0.75
Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet (2009) 5.82
Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol (2007) 5.23
Statin use and risk of prostate cancer recurrence in men treated with radiation therapy. J Clin Oncol (2010) 4.39
Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA (2004) 4.10
Adjuvant radiotherapy and chemotherapy for pancreatic carcinoma: the Mayo Clinic experience (1975-2005). J Clin Oncol (2008) 3.15
An electronic application for rapidly calculating Charlson comorbidity score. BMC Cancer (2004) 3.06
Consensus guidelines for delineation of clinical target volume for intensity-modulated pelvic radiotherapy in postoperative treatment of endometrial and cervical cancer. Int J Radiat Oncol Biol Phys (2007) 2.34
Boost radiotherapy in young women with ductal carcinoma in situ: a multicentre, retrospective study of the Rare Cancer Network. Lancet Oncol (2006) 2.32
Frameless, real-time, surface imaging-guided radiosurgery: clinical outcomes for brain metastases. Neurosurgery (2012) 2.20
Intensity-modulated whole pelvic radiotherapy in women with gynecologic malignancies. Int J Radiat Oncol Biol Phys (2002) 2.03
Dosimetric predictors of acute hematologic toxicity in cervical cancer patients treated with concurrent cisplatin and intensity-modulated pelvic radiotherapy. Int J Radiat Oncol Biol Phys (2006) 1.89
Intensity-modulated radiation therapy (IMRT) in the treatment of anal cancer: toxicity and clinical outcome. Int J Radiat Oncol Biol Phys (2005) 1.85
Population-based study of competing mortality in head and neck cancer. J Clin Oncol (2011) 1.82
Adjuvant chemoradiation for pancreatic adenocarcinoma: the Johns Hopkins Hospital-Mayo Clinic collaborative study. Ann Surg Oncol (2010) 1.79
Intensity-modulated radiation therapy use in the U.S., 2004. Cancer (2005) 1.78
Testicular cancer survivorship: research strategies and recommendations. J Natl Cancer Inst (2010) 1.76
Targeting of osseous sites with alpha-emitting 223Ra: comparison with the beta-emitter 89Sr in mice. J Nucl Med (2003) 1.76
Histologic response of dose-intense chemotherapy with preoperative hypofractionated radiotherapy for patients with high-risk soft tissue sarcomas. Cancer (2008) 1.75
Consensus guidelines for delineation of clinical target volume for intensity-modulated pelvic radiotherapy for the definitive treatment of cervix cancer. Int J Radiat Oncol Biol Phys (2010) 1.73
A survey of stereotactic body radiotherapy use in the United States. Cancer (2011) 1.71
Stereotactic body radiotherapy for multisite extracranial oligometastases: final report of a dose escalation trial in patients with 1 to 5 sites of metastatic disease. Cancer (2011) 1.70
An initial report of a radiation dose-escalation trial in patients with one to five sites of metastatic disease. Clin Cancer Res (2008) 1.68
Association between bone marrow dosimetric parameters and acute hematologic toxicity in anal cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys (2007) 1.62
MIRD Pamphlet No. 22 (abridged): radiobiology and dosimetry of alpha-particle emitters for targeted radionuclide therapy. J Nucl Med (2010) 1.61
Impact of intensity-modulated radiotherapy on acute hematologic toxicity in women with gynecologic malignancies. Int J Radiat Oncol Biol Phys (2002) 1.61
Preliminary analysis of chronic gastrointestinal toxicity in gynecology patients treated with intensity-modulated whole pelvic radiation therapy. Int J Radiat Oncol Biol Phys (2003) 1.59
Dosimetric comparison of bone marrow-sparing intensity-modulated radiotherapy versus conventional techniques for treatment of cervical cancer. Int J Radiat Oncol Biol Phys (2008) 1.57
Incidence of radiation pneumonitis after thoracic irradiation: Dose-volume correlates. Int J Radiat Oncol Biol Phys (2007) 1.54
Intensity-modulated radiotherapy in treatment of pancreatic and bile duct malignancies: toxicity and clinical outcome. Int J Radiat Oncol Biol Phys (2004) 1.52
Complete pathologic response after neoadjuvant chemoradiotherapy for esophageal cancer is associated with enhanced survival. Ann Thorac Surg (2009) 1.51
A dosimetric analysis of intensity-modulated radiation therapy (IMRT) as an alternative to adjuvant high-dose-rate (HDR) brachytherapy in early endometrial cancer patients. Int J Radiat Oncol Biol Phys (2006) 1.50
Chronic genitourinary and gastrointestinal toxicity of prostate cancer patients undergoing pelvic radiotherapy with intensity-modulated versus 4-field technique. Am J Clin Oncol (2007) 1.49
Intensity-modulated radiotherapy as a means of reducing dose to bone marrow in gynecologic patients receiving whole pelvic radiotherapy. Int J Radiat Oncol Biol Phys (2003) 1.46
MicroRNA expression characterizes oligometastasis(es). PLoS One (2011) 1.45
Improved survival time trends for glioblastoma using the SEER 17 population-based registries. J Neurooncol (2011) 1.42
Toxicity after external beam radiotherapy for prostate cancer: an analysis of late morbidity in men with diabetes mellitus. Urology (2013) 1.40
Head and neck cancers, Version 2.2014. Clinical practice guidelines in oncology. J Natl Compr Canc Netw (2014) 1.39
Neoadjuvant versus induction chemotherapy: more than semantics. J Clin Oncol (2013) 1.39
Therapeutic options for a rising PSA after radical prostatectomy. Can J Urol (2013) 1.38
Long-term outcome of concurrent chemotherapy and reirradiation for recurrent and second primary head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys (2005) 1.38
Adjuvant therapy for gallbladder carcinoma: the Mayo Clinic Experience. Int J Radiat Oncol Biol Phys (2009) 1.34
A multi-institutional matched-control analysis of adjuvant and salvage postoperative radiation therapy for pT3-4N0 prostate cancer. Urology (2008) 1.32
Late toxicity after intensity-modulated radiation therapy for localized prostate cancer: an exploration of dose-volume histogram parameters to limit genitourinary and gastrointestinal toxicity. Int J Radiat Oncol Biol Phys (2010) 1.30
Extensive inguinal lymphadenectomy improves overall 5-year survival in penile cancer patients: results from the Surveillance, Epidemiology, and End Results program. Cancer (2010) 1.28
Age and grade trends in prostate cancer (1974-2003): a Surveillance, Epidemiology, and End Results Registry analysis. Am J Clin Oncol (2008) 1.28
Clinical outcomes of intensity-modulated pelvic radiation therapy for carcinoma of the cervix. Int J Radiat Oncol Biol Phys (2010) 1.25
Small cell (neuroendocrine) carcinoma of the prostate: etiology, diagnosis, prognosis, and therapeutic implications--a retrospective study of 30 patients from the rare cancer network. Am J Med Sci (2008) 1.23
Primary spinal epidural lymphoma: patients' profile, outcome, and prognostic factors: a multicenter Rare Cancer Network study. Int J Radiat Oncol Biol Phys (2006) 1.22
Normal tissue complication probability modeling of acute hematologic toxicity in cervical cancer patients treated with chemoradiotherapy. Int J Radiat Oncol Biol Phys (2010) 1.22
Quantitative evaluation of a cone-beam computed tomography-planning computed tomography deformable image registration method for adaptive radiation therapy. J Appl Clin Med Phys (2007) 1.21
External beam radiotherapy for prostate cancer: urinary outcomes for men with high International Prostate Symptom Scores (IPSS). Int J Radiat Oncol Biol Phys (2010) 1.21
A historical prospective cohort study of carotid artery stenosis after radiotherapy for head and neck malignancies. Int J Radiat Oncol Biol Phys (2005) 1.20
The role of radiotherapy in locally advanced pancreatic carcinoma. Nat Rev Gastroenterol Hepatol (2010) 1.18
Treatment results of 165 pediatric patients with non-metastatic nasopharyngeal carcinoma: a Rare Cancer Network study. Radiother Oncol (2006) 1.17
Early pulmonary toxicity following lung stereotactic body radiation therapy delivered in consecutive daily fractions. Radiother Oncol (2011) 1.17
Aspirin use and the risk of prostate cancer mortality in men treated with prostatectomy or radiotherapy. J Clin Oncol (2012) 1.17
A multi-institutional acute gastrointestinal toxicity analysis of anal cancer patients treated with concurrent intensity-modulated radiation therapy (IMRT) and chemotherapy. Radiother Oncol (2009) 1.16
Prostate cancer and race. Curr Probl Cancer (2007) 1.15
Proton beam radiotherapy versus three-dimensional conformal stereotactic body radiotherapy in primary peripheral, early-stage non-small-cell lung carcinoma: a comparative dosimetric analysis. Int J Radiat Oncol Biol Phys (2009) 1.15
Patterns of care in palliative radiotherapy: a population-based study. J Oncol Pract (2013) 1.13
Population-based case-control study of recreational drug use and testis cancer risk confirms an association between marijuana use and nonseminoma risk. Cancer (2012) 1.13
Prospective study of functional bone marrow-sparing intensity modulated radiation therapy with concurrent chemotherapy for pelvic malignancies. Int J Radiat Oncol Biol Phys (2012) 1.12
Oligo- and polymetastatic progression in lung metastasis(es) patients is associated with specific microRNAs. PLoS One (2012) 1.11
A dosimetric analysis of acute gastrointestinal toxicity in women receiving intensity-modulated whole-pelvic radiation therapy. Radiother Oncol (2003) 1.11
Incorporation of SPECT bone marrow imaging into intensity modulated whole-pelvic radiation therapy treatment planning for gynecologic malignancies. Radiother Oncol (2005) 1.11
Resectable pancreatic small cell carcinoma. Rare Tumors (2011) 1.11
Evaluation of adjuvant chemoradiation therapy for ampullary adenocarcinoma: the Johns Hopkins Hospital-Mayo Clinic collaborative study. Radiat Oncol (2011) 1.10
A survey of image-guided radiation therapy use in the United States. Cancer (2010) 1.10